Dalfampridine NDC 82249-702

NDC codes

FDA NDC Directory

Product NDC (as listed)82249-702Labeler and product segments. Claims need a package NDC.

Product NDC at billing width82249-0702Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
82249-702-60	82249070260	60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (82249-702-60)Marketed from Jul 21, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Dalfampridine
Generic name (nonproprietary): dalfampridine
Active ingredients: Dalfampridine — 10 mg/1
Dosage form: Tablet, Film coated, Extended release
Route: Oral
Labeler: CivicaScript LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 206765
Marketing start: Jul 21, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Potassium Channel Antagonists (Mechanism)
Identifiers: Product ID 82249-702_c40dcc84-b839-44aa-94f2-886fb1c3d75cSPL ID c40dcc84-b839-44aa-94f2-886fb1c3d75cSPL set ID c40dcc84-b839-44aa-94f2-886fb1c3d75cRxCUI 897021UNII BH3B64OKL9
Pharmacologic class: Potassium Channel Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N482249070260 followed by a unit qualifier and the quantity

Package 82249-0702-60. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 16, 2025.

Indications (excerpt from the label)

Dalfampridine extended-release tablets are indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed [see Clinical Studies (14) ]. Dalfampridine is a potassium channel blocker indicated to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed ( 1 , 14 ).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 206765

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 206765
Product	Strength	Form · route	Labeler	Product NDC
Dalfampridine	Dalfampridine 10 mg/1	Tablet, Film coated, Extended releaseOral	Ascend Laboratories, LLC	67877-444
Dalfampridine	Dalfampridine 10 mg/1	Tablet, Film coated, Extended releaseOral	Golden State Medical Supply, Inc.	51407-876